Objective Since HFMD was designated as a class C communicable disease in May 2008,18 months surveillance data have been accumulated to December 2009.This article was to describe the distribution of HFMD for age,sex,ar...Objective Since HFMD was designated as a class C communicable disease in May 2008,18 months surveillance data have been accumulated to December 2009.This article was to describe the distribution of HFMD for age,sex,area,and time between 2008 and 2009,to reveal the characteristics of the epidemic.Methods We analyzed weekly reported cases of HFMD from May 2008 to December 2009,and presented data on the distribution of age,sex,area and time.A discrete Poisson model was used to detect spatial-temporal clusters of HFMD.Results More than 1 065 000 cases of HFMD were reported in China's Mainland from May 2008 to December 2009 （total incidence：12.47 per 10 000）.Male incidence was higher than female for all ages and 91.9% of patients were 5 years old.The incidence was highest in Beijing,Shanghai,Zhejiang and Hainan.The highest peak of HFMD cases was in April and the number of cases remained high from April to August.The spatial-temporal distribution detected four clusters.Conclusion Children 5 years old were susceptible to HFMD and we should be aware of their vulnerability.The incidence was higher in urban than rural areas,and an annual pandemic usually starts in April.展开更多
目的评价冠状动脉腔内注射重组人尿激酶原对急性ST段抬高心肌梗死(STEMI)高血栓负荷冠状动脉介入(PCI)治疗效果的影响。方法选择2016年8月至2018年12月就诊于安徽医科大学附属六安医院诊断STEMI并接受急诊PCI的冠状动脉高血栓负荷病人12...目的评价冠状动脉腔内注射重组人尿激酶原对急性ST段抬高心肌梗死(STEMI)高血栓负荷冠状动脉介入(PCI)治疗效果的影响。方法选择2016年8月至2018年12月就诊于安徽医科大学附属六安医院诊断STEMI并接受急诊PCI的冠状动脉高血栓负荷病人126例,采用随机数字表法分为对照组与观察组,对照组65例应用抽吸导管抽吸血栓,冠状动脉腔内注射盐酸替罗非班,观察组61例应用抽吸导管抽吸血栓,冠状动脉腔内注射替罗非班及重组人尿激酶原。观察两组临床疗效及安全性。结果观察组在靶血管TIMI3级血流[59(96.7%)例比51(78.5%)例]、术后2 h ST段回落百分比[28(45.9%)例比17(26.2%)例]优于对照组(P<0.05),靶血管无复流/慢血流发生率低于对照组[2(3.3%)例比10(15.4%)例,P<0.01]。3个月时观察组LVEF[(52±8)%比(44±9)%]、LVEDd[(46±4)mm比(59±6)mm]优于对照组(均P<0.05)。两组3个月内MACE发生率及出血例数差异无统计学意义(P>0.05)。结论重组人尿激酶原对急性ST段抬高心肌梗死高血栓负荷病人明显改善预后,减少心血管事件的发生,疗效可靠且安全。展开更多
文摘Objective Since HFMD was designated as a class C communicable disease in May 2008,18 months surveillance data have been accumulated to December 2009.This article was to describe the distribution of HFMD for age,sex,area,and time between 2008 and 2009,to reveal the characteristics of the epidemic.Methods We analyzed weekly reported cases of HFMD from May 2008 to December 2009,and presented data on the distribution of age,sex,area and time.A discrete Poisson model was used to detect spatial-temporal clusters of HFMD.Results More than 1 065 000 cases of HFMD were reported in China's Mainland from May 2008 to December 2009 （total incidence：12.47 per 10 000）.Male incidence was higher than female for all ages and 91.9% of patients were 5 years old.The incidence was highest in Beijing,Shanghai,Zhejiang and Hainan.The highest peak of HFMD cases was in April and the number of cases remained high from April to August.The spatial-temporal distribution detected four clusters.Conclusion Children 5 years old were susceptible to HFMD and we should be aware of their vulnerability.The incidence was higher in urban than rural areas,and an annual pandemic usually starts in April.
文摘目的评价冠状动脉腔内注射重组人尿激酶原对急性ST段抬高心肌梗死(STEMI)高血栓负荷冠状动脉介入(PCI)治疗效果的影响。方法选择2016年8月至2018年12月就诊于安徽医科大学附属六安医院诊断STEMI并接受急诊PCI的冠状动脉高血栓负荷病人126例,采用随机数字表法分为对照组与观察组,对照组65例应用抽吸导管抽吸血栓,冠状动脉腔内注射盐酸替罗非班,观察组61例应用抽吸导管抽吸血栓,冠状动脉腔内注射替罗非班及重组人尿激酶原。观察两组临床疗效及安全性。结果观察组在靶血管TIMI3级血流[59(96.7%)例比51(78.5%)例]、术后2 h ST段回落百分比[28(45.9%)例比17(26.2%)例]优于对照组(P<0.05),靶血管无复流/慢血流发生率低于对照组[2(3.3%)例比10(15.4%)例,P<0.01]。3个月时观察组LVEF[(52±8)%比(44±9)%]、LVEDd[(46±4)mm比(59±6)mm]优于对照组(均P<0.05)。两组3个月内MACE发生率及出血例数差异无统计学意义(P>0.05)。结论重组人尿激酶原对急性ST段抬高心肌梗死高血栓负荷病人明显改善预后,减少心血管事件的发生,疗效可靠且安全。
